Trial Profile

Clinical Trial on the Safety and Effectiveness of Subretinal Injection of NGGT001 for Treating Crystalline Retinal Degeneration

Status: Active, no longer recruiting

Phase of Trial: Phase 0

Latest Information Update: 25 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NGGT 001 (Primary)
Indications Bietti crystalline dystrophy; Retinal degeneration
Focus Adverse reactions

Most Recent Events

17 Aug 2026 Protocol amended to change number of arms form 2 to 4, primary end point BCVA ETDRS visual acuity removed.
17 Aug 2026 Actual primary completion date changed to 25 Nov 2024.
17 Aug 2026 Planned End Date changed from 29 May 2028 to 25 Nov 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com